Leah Kuntz

After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.

What are the top 6 disappointing psychopharmacological updates from the past year? We rank the top 6.

Psychiatric Times is pleased to present a brand-new section on media and psychiatry, and section editor, Mena Mirhom, MD, FAPA.

A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.

New phase 3 data on CYB003 is coming. Learn more about the phase 3 pivotal program here.

In mice models, opioid delta-receptor agonists showed promise in helping to relieve abdominal pain and regulate bowel movements. Is targeting the brain the best path forward for IBS treatment?

Do you want to be featured in a future Special Report? Check out our February theme!

Check out the pipeline updates from January!

Meditation using immersive virtual reality devices can help alleviate symptoms of major depressive disorder and generalized anxiety disorder.

According to a new study, the launch of 988 did not equate to significant, equitable growth in availability of crisis services.

New positive results of a pharmacokinetics study of AD04 for alcohol use disorder confirms the near micro-dosing regimen planned for upcoming trials.

Check out new positive topline results from the open-label phase 2A study of BPL-003 in participants with moderate-to-severe alcohol use disorder.

Neurocrine is initiating a phase 3 study of osavampator for the treatment of adults with major depressive disorder.

According to a new label update, the transfer of Qelbree into breastmilk is low.

Check out some of the top clinical pearls gleaned from presenters at Real Psychiatry.

The FDA has approved the supplemental New Drug Application for Spravato, the first and only monotherapy for adults with treatment-resistant depression.

Check out these top tips for treating postpartum depression from the Real Psychiatry conference!

Digital therapeutics may help improve negative symptoms associated with schizophrenia.

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.

Are you attending Real Psychiatry this weekend?

The FDA grants Breakthrough Device Designation to Spear Bio’s pTau 217 blood test for Alzheimer disease.

Johnson & Johnson today announced that they will acquire all outstanding shares of Intra-Cellular Therapies, as well as their therapeutic pipeline, including lumateperone.

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

Do you want to be featured in a future Special Report? Check out our January theme!

Navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial.

Let's review the Special Reports of 2024!

Need CME credit? We've got a present for you!

A recent longitudinal, retrospective study aimed to examine antipsychotic prescribing and rehospitalization rates in a forensic psychiatric sample.

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.